BCM
APLT

Beaumont Capital Management’s Applied Therapeutics APLT Stock Holding History

Beaumont Capital Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,403
Closed -$6.29K – 38
2025
Q3 		$6.29K Buy
+10,403
New +$4.9K ﹤0.01% 47

Other funds holding APLT

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Beaumont Capital Management's APLT Position: Q4 2025 in Review

Beaumont Capital Management sold out of Applied Therapeutics (APLT) in Q4 2025, closing a stake of 10,403 shares — an estimated $6.29K sold.

Beaumont Capital Management first reported a position in APLT in Q3 2025 and held it in 1 quarter. The position peaked at $6.29K in Q3 2025. 52 funds tracked by Wall St. Rank hold APLT as of Q4 2025.

  • Beaumont Capital Management reported no remaining Applied Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Beaumont Capital Management sold 10,403 Applied Therapeutics shares in Q4 2025, an estimated $6.29K.
  • Beaumont Capital Management first reported a position in Applied Therapeutics in Q3 2025 and held it in 1 quarter.
  • Beaumont Capital Management's Applied Therapeutics position peaked at $6.29K in Q3 2025.
  • 52 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2025.

Based on Beaumont Capital Management's 13F filing for Q4 2025, filed 10 Feb 2026.